CORDIS - EU research results
CORDIS

Proof of concept of prognostic test for critical Septic Patients based in Early Detection of NLRP3 Inflammasome impairment activation.

Project description

Point-of-care testing kit for the early sepsis prognosis

Sepsis causes a systemic inflammatory response driven by proinflammatory cytokines and is the leading cause of death in hospital critical care units. Early disease biomarkers are necessary to assist in the decision-making identification of immunocompromised patients. The development of a point-of-care testing kit to enable quick and reliable detection of immunocompromised patients by using blood biomarkers would improve the early prognosis of sepsis. Recently, an in vitro prognostic product was developed that enables the fast detection of early impairment of the NLRP3 inflammasome activation, as a prognostic biomarker in sepsis. The objective of the current EU-funded SPEDI-TEST project is to demonstrate the technical and commercial feasibility, and evaluate the new business opportunity of the clinical introduction of this novel test.

Objective

Sepsis remains the leading cause of death in critical care units of Hospitals, affecting more that 18 million people worldwide and causes a systemic inflammatory response driven by the production of proinflammatory cytokines. Several studies have been conducted to find out whether data mining and machine learning could be used to identify patients at risk of sepsis. Although the currently available biomarkers can help shorten this decision process, there is still a need for additional early disease biomarkers that could anticipate the decision-making identifying immunocompromised septic patients. In this sense, ongoing efforts in the development of a point-of-care testing kit, enabling quick and reliable detection of immunocompromised patients by using blood biomarkers, will aid greatly the early prognosis of sepsis. In this scenario, the prognosis and therapy selection still remains a clinical decision by assessing the patient’s history, symptoms of infection, and development of acute organ dysfunction. Our group have determined under the ERC consolidator grant ref. 614578 (DangerATP) that during the initial 24 h of the inflammatory response in sepsis, monocytes from human septic patients present an early impairment of the activation of the NLRP3 inflammasome that is associated with higher late mortality. This group of septic patients was not identified with any of the clinical or biochemical determinations performed.
We have developed an in vitro prognostic (IVD) product for the fast detection in less than 4 hours of early impairment of the NLRP3 inflammasome activation, as a biomarker for the prognosis in sepsis. This IVD will be used in intensive care units and immunology units of hospitals. The objective of the action is to demonstrate the technical and commercial feasibility and evaluate the new business opportunity of introducing this novel IVD product.

Host institution

FUNDACION PARA LA FORMACION E INVESTIGACION SANITARIAS DE LA REGION DE MURCIA
Net EU contribution
€ 148 125,00
Address
CALLE CAMPO 12 PABELLON DOCENTE DEL HOSPITAL CLINICO UNIVERSITARIO VIRGEN DE LA ARRIXACA 3 PLANTA EL PALMA
30120 Murcia
Spain

See on map

Region
Sur Región de Murcia Murcia
Activity type
Research Organisations
Links
Total cost
No data

Beneficiaries (2)